ArticleBulletin of experimental biology and medicine2026
Comparison of the Effects of Nicorandil and Sodium Nitroprusside on the Progression of Microvascular Obstruction in the Myocardial Infarction Zone in Rats.
Article in Bulletin of experimental biology and medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies have shown that exogenous nitric oxide alleviates tissue injury caused by ischemia and reperfusion. The multitarget drug nicorandil possessing a dual mechanism of action combining the release of nitric oxide with opening of ATP-dependent K channels seems promising. We studied the infarction-limiting effect of nicorandil and its impact on the progression of the no-reflow/slow flow phenomenon in the myocardial infarction zone in rats compared to sodium nitroprusside. In a rat in vivo model of regional myocardial ischemia and reperfusion, neither nicorandil nor sodium nitroprusside reduced myocardial infarction size in rats with early no-reflow. Despite the dual mechanism of action of nicorandil (0.2 mg/kg), sodium nitroprusside (60 μg/kg) was more effective in reducing the size of the early no-reflow zone, and a trend toward a decrease in the no-reflow zone was observed at the end of 2‑h reperfusion.
Indexed as
Identifiers
42776327What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.